In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...

Novo Nordisk’s 2026 outlook reflects this shift with an adjusted basis excluding the non-recurring reversal of $4.2 billion in 340B Drug Pricing Program rebate provisions. 1 Sales and operating profit ...

Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...

The organization’s 2026 Breast Cancer Progress Outlook reflects the positive progress in early detection and awareness, showing that breast cancer mortality in the United States has declined 44% ...

Dave Carey, CEO, Preceptis Medical and Michael Monovoukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven ...

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...

According to public statements and social media posts from X, ACIP vice chair Robert Malone (a public ally of HHS secretary Robert F. Kennedy Jr.) publicly accused FDA Commissioner Marty Makary of ...

PE: What was your experience debuting Trialynx at JP Morgan Healthcare 2026? Schwab: It’s fantastic. This was the culmination ...

On February 1, FDA announced a new pilot program designed to promote the construction of domestic manufacturing sites, along ...